The global market for generic drugs will continue to grow in the coming years, coinciding with the expiry of patents for key blockbuster drugs and with healthcare policies increasingly oriented towards cost containment. In addition, the balance of health care costs will lean more and more towards emerging markets such as China, India, Brazil and Russia. These are the two salient points of an analysis conducted by Frost & Sullivan from which it would emerge that the market for equivalents should grow from 123.85 billion dollars in revenues in 2010 to 231 in 2017. «The expiry of many patents in the period considered (2010- 2017)» underlines a note from the international consultancy firm «will accelerate the growth of the generics market. The trend» continues the note «goes towards less competitive sectors at the moment, albeit very attractive ones such as that of "difficult to produce" generics, specialty generics and biosimilars». Positive signals for this market partly dampened by increasingly stringent regulatory systems and price control systems imposed by governments. Aspects that could reduce, concludes Frost & Sullivan, the profit margins of generic producers.
18 January 2012 – Pharmacist33
India, +15% retail sales in 2011
The Indian pharmaceutical retail market recorded robust growth of 15% during 2011, mainly due to medicines such as anti-diabetic, anti-infective and skin disease products, as well as vitamins. The pharmaceutical sector has continued to show its resilience despite concerns over the slowdown in the economy, according to data from the 'All India Organization of Chemists and Druggists', which document a new milestone in overall sales of 60,000 rupees. for 2011. The pharmaceutical market in general increased by 15.7% in the month of December alone, with still the strongest growth in key therapeutic areas such as anti-diabetics, dermatological products and vitamins. While the growth of anti-infectives and painkillers and analgesics, equal to 11% and 12% respectively, was slower. Again in December 2011, the companies that recorded the best performance were Glenmark, Sun Pharma, Pfizer and Ipca Laboratoires.
January 18, 2012 – PharmaKronos
